Enrique Conterno, via Eli Lilly
As questions swirl around lead drug, FibroGen (and AstraZeneca) find a new champion from Big Pharma
Two months after Enrique Conterno left his high-profile post as the head of Lilly Diabetes and Lilly USA, the 27-year pharma vet is back in the game — this time as the newly appointed CEO of a closely-watched biotech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.